Our research goal is to discover targets for new and safe anti-thrombotics, and improve on current treatments, which are not effective or have bleeding side effects. For example, one in six patients who have had a heart attack will have another attack despite optimal treatment.
New diagnostics are important because routine tests are not able to detect a thrombotic tendency in half the cases.
Our group has a special interest in the development of biochips for the detection and monitoring of thrombotic tendency.
We are focused on the role of enzymes, named thiol isomerases, in the development of thrombosis (blood clots) and their potential as novel antithrombotic targets.
In the clinical space, we are interested in the management of venous thrombosis in the community and high-risk thrombosis, as thrombosis can have severe consequences such as heart attack and stroke.
We aim to find answers to fundamental biological problems that will enable the development of new diagnostics and treatments for patients with blood clots.
Bekendam RH, et al. Protein disulfide isomerase regulation by nitric oxide maintains vascular quiescence and controls thrombus formation. J Thromb Haemost. 2018 Sep 12, IF:4.8.
Passam F, et al. Mechano-redox control of integrin de-adhesion. Elife. 2018 Jun 22;7, IF:7.7.
Lee KH, et al. Quantification of NETs-associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis. Int J Lab Hematol. 2018 Mar 9, IF:1.9.
Butera D, et al. Autoregulation of von Willebrand factor function by a disulfide bond switch. Sci Adv. 2018 Feb 28;4(2), IF:11.5.
Dupuy A, et al. Functional assays of thiol isomerase ERp5. Methods in Molecular Biology 2018 [in press].